Welcome to our dedicated page for Innovate news (Ticker: VATE), a resource for investors and traders seeking the latest updates and insights on Innovate stock.
INNOVATE Corp. reports developments across a diversified portfolio organized around Infrastructure, Life Sciences and Spectrum. News commonly covers consolidated earnings, subsidiary performance, DBM Global cash dividends, steel construction activity, Spectrum network and broadcasting updates, and capital or operating developments within portfolio companies.
Life Sciences updates center on MediBeacon, an equity method investment developing fluorescent tracer agents and transdermal detection for kidney function assessment through the TGFR System, including FDA, NMPA and CE Mark regulatory milestones. INNOVATE also reports R2 system sales and commercial agreements as part of its portfolio-company operating updates.
INNOVATE Corp (NYSE: VATE) reported first quarter 2026 revenue of $364.8 million, up 33% year over year, driven mainly by Infrastructure. Net loss attributable to common and participating preferred stockholders improved to $17.2 million from $24.8 million, while Total Adjusted EBITDA rose to $19.7 million from $7.2 million.
Infrastructure revenue grew 35.1% to $357.9 million with net income of $9.3 million. Life Sciences saw MediBeacon secure a CE mark in Europe, and R2 expanded internationally. Spectrum revenue declined to $5.3 million amid advertising softness. Cash and equivalents increased to $134.6 million.
INNOVATE Corp. (NYSE: VATE) will report first quarter 2026 financial results on May 14, 2026 after market close and will host an earnings conference call the same day at 4:30 p.m. ET.
The call will be broadcast live on INNOVATE’s Investor Relations website and a replay will be available approximately three hours after the call through May 28, 2026. Dial-in and replay numbers are provided for domestic and international attendees.
INNOVATE (NYSE: VATE) said DBM Global Inc., its operating subsidiary, will pay a $3.0 million cash dividend (about $0.78 per share) on April 28, 2026 to stockholders of record as of April 13, 2026.
INNOVATE, as DBMG’s largest stockholder, expects to receive ~$2.7 million; INNOVATE individual stockholders are not eligible for the payout.
INNOVATE (NYSE: VATE) said MediBeacon, an equity-method investment, received EU CE Mark under MDR for its TGFR Monitor and TGFR Reusable Sensor (both Class IIa).
The certified devices join the CE marked TGFR Disposable Ring and Lumitrace injection (approved in U.S. and China; EU submission pending) to form the TGFR System for transdermal GFR assessment, enabling potential inclusion in European clinical trials later in 2026.
INNOVATE (NYSE: VATE) reported fourth-quarter and full-year 2025 results on March 26, 2026. Q4 revenue was $382.7M (+61.7% YoY) and FY2025 revenue was $1,246.0M (+12.5% YoY). Q4 net loss attributable to common stockholders was $7.8M (loss per share $0.58). Total Adjusted EBITDA for Q4 was $24.5M. Infrastructure backlog expanded to $1.8B. Cash and equivalents were $112.1M at year-end.
Highlights included DBMG margin compression, FDA approval and MediBeacon commercialization steps, a 600‑system China commitment for R2, and Spectrum ad softness with expected 2026 benefits.
INNOVATE Corp (NYSE: VATE) will report its fourth quarter and full year 2025 results on March 26, 2026 after market close. A live earnings conference call will follow at 4:30 p.m. ET the same day and will be webcast on the company Investor Relations website.
Dial-in and replay details are provided for domestic and international participants; a replay will be available through April 9, 2026.
INNOVATE (NYSE: VATE) holds a 44.7% equity interest in MediBeacon, whose transdermal GFR (TGFR) article was named one of five 2025 JASN Editor’s Choice articles and was the August 2025 JASN cover feature. Centers of Excellence commercialization of the MediBeacon Transdermal GFR System began in January 2026.
The TGFR System uses Lumitrace (relmapirazin) injection, a monitor and reusable sensor to provide a point-of-care transdermal measurement of glomerular filtration rate, targeted initially at heart failure monitoring, transplant evaluation and oncology drug dosing.
INNOVATE (NYSE: VATE) said DBM Global Inc., its operating subsidiary, will pay a $5.0 million cash dividend (about $1.30 per share) on Feb 24, 2026 to stockholders of record as of Feb 9, 2026. INNOVATE, as DBMG’s largest stockholder, expects to receive roughly $4.6 million of the payout. Individual INNOVATE shareholders are not eligible for this dividend.
INNOVATE (NYSE:VATE) holds a 44.7% equity interest in MediBeacon, which received FDA approval on December 16, 2025 for the next‑generation MediBeacon® TGFR™ System including the new TGFR Reusable Sensor.
The TGFR System measures clearance of Lumitrace® (relmapirazin) transdermally to assess kidney function at the point of care. The reusable sensor is designed for patient comfort, reusability via a disposable adhesive ring, and lower cost versus the previously approved single‑use sensor. MediBeacon highlighted a lead JASN cover article (August 2025) and cites >700 preclinical publications. Early access commercialization at select academic medical centers in the US and China is expected to begin in Q1 2026.
INNOVATE Corp (NYSE: VATE) reported third quarter 2025 consolidated revenue of $347.1M, up 43.3% year-over-year, driven by Infrastructure growth. Total Adjusted EBITDA was $19.8M, up 17.9% year-over-year. Net loss attributable to common stockholders narrowed to $9.4M (loss per share $0.71).
Key operational items: DBM Global revenue rose to $338.4M (+45.4%) with adjusted backlog of $1.6B. MediBeacon received NMPA approval to sell the Transdermal GFR System in China and expects sales before year-end. The company completed refinancing transactions but missed milestone dates, triggering sales/strategic processes for DBMG and HC2 Broadcasting.